uniQure N.V. - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

uniQure N.V. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'uniQure N.V. - Product Pipeline Review - 2015', provides an overview of the uniQure N.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of uniQure N.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of uniQure N.V. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of uniQure N.V.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the uniQure N.V.'s pipeline products

Reasons to Buy

- Evaluate uniQure N.V.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of uniQure N.V. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the uniQure N.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of uniQure N.V. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of uniQure N.V.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of uniQure N.V. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
uniQure N.V. Snapshot 5
uniQure N.V. Overview 5
Key Information 5
Key Facts 5
uniQure N.V. - Research and Development Overview 6
Key Therapeutic Areas 6
uniQure N.V. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
uniQure N.V. - Pipeline Products Glance 12
uniQure N.V. - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
uniQure N.V. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
uniQure N.V. - Drug Profiles 14
AMT-060 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
AMT-110 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AMT-021 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AMT-090 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Gene Therapy for Hemophilia A 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy to Activate S100-A1 for Congestive Heart Failure 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
RNAi Gene Therapy to Inhibit Huntingtin for Huntington's Disease 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
uniQure N.V. - Pipeline Analysis 24
uniQure N.V. - Pipeline Products by Target 24
uniQure N.V. - Pipeline Products by Route of Administration 25
uniQure N.V. - Pipeline Products by Molecule Type 26
uniQure N.V. - Pipeline Products by Mechanism of Action 27
uniQure N.V. - Recent Pipeline Updates 28
uniQure N.V. - Dormant Projects 31
uniQure N.V. - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
alipogene tiparvovec 32
AMT-080 32
uniQure N.V. - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables

uniQure N.V., Key Information 5
uniQure N.V., Key Facts 5
uniQure N.V. - Pipeline by Indication, 2015 7
uniQure N.V. - Pipeline by Stage of Development, 2015 8
uniQure N.V. - Monotherapy Products in Pipeline, 2015 9
uniQure N.V. - Partnered Products in Pipeline, 2015 10
uniQure N.V. - Partnered Products/ Combination Treatment Modalities, 2015 11
uniQure N.V. - Phase I, 2015 12
uniQure N.V. - Preclinical, 2015 13
uniQure N.V. - Pipeline by Target, 2015 24
uniQure N.V. - Pipeline by Route of Administration, 2015 25
uniQure N.V. - Pipeline by Molecule Type, 2015 26
uniQure N.V. - Pipeline Products by Mechanism of Action, 2015 27
uniQure N.V. - Recent Pipeline Updates, 2015 28
uniQure N.V. - Dormant Developmental Projects,2015 31
uniQure N.V. - Discontinued Pipeline Products, 2015 32
uniQure N.V., Subsidiaries 33